Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets 12:26:20 2026-05-05 EDT			5-day change	1st Jan Change
0.000300 ^USD	+200.00%		+200.00%	+200.00%

23-06-14	Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	CI
23-03-31	Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Market Cap	146K 126K 119K 108K 203K 14.01M 206K 1.39M 546K 7M 549K 537K 23.33M	P/E 2021	-0.43x	P/E 2022	-0.41x
Enterprise Value	-23.64M -20.42M -19.21M -17.46M -32.84M -2.26B -33.32M -225M -88.31M -1.13B -88.75M -86.83M -3.77B	EV / Sales 2021	-0.68x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

23-06-14	Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	CI
23-03-31	Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	Calithera Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
23-02-06	Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from S&P TMI Index	CI
23-02-01	Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite Index	CI
23-01-25	Top Premarket Decliners	MT
23-01-25	Calithera Biosciences Shares Set to be Suspended From Nasdaq on Feb. 2; Stock Declines Premarket	MT
23-01-09	Top Midday Decliners	MT
23-01-09	Calithera Biosciences to Proceed With Liquidation and Dissolution of Company	MT
23-01-09	Calithera Biosciences, Inc. Announces Departure of Susan M. Molineaux as Chief Executive Officer	CI
23-01-09	Calithera Biosciences, Inc. Announces Departure of Stephanie Wong as Chief Financial Officer	CI
23-01-09	Calithera Biosciences, Inc. Announces Executive Departures	CI
23-01-04	Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; Shares Climb 10%	MT

22-11-15	Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral From Buy	MT
22-11-15	SVB Securities Downgrades Calithera Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $18	MT
22-08-29	HC Wainwright Upgrades Calithera Biosciences to Buy From Neutral; Price Target is $8	MT
22-04-04	SVB Leerink Adjusts Calithera Biosciences' Price Target to $2 from $3, Keeps Outperform Rating	MT
22-01-31	Ladenburg Thalmann Starts Calithera Biosciences at Buy with $4 Price Target	MT

Calithera Biosciences, Inc. Stock

Stocks

CALA

US13089P5070

Pharmaceuticals

Valuation: Calithera Biosciences, Inc.

Chart: Calithera Biosciences, Inc.

Latest news : Calithera Biosciences, Inc.

Analysts' recommendations: Calithera Biosciences, Inc.

Press Releases: Calithera Biosciences, Inc.

News in other languages: Calithera Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Calithera Biosciences, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

23-01-25	CALITHERA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-01-09	CALITHERA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
23-01-09	Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution	AQ
22-11-14	Calithera: Q3 Earnings Snapshot	AQ
22-11-14	CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

15-03-06	Apple : Les valeurs à suivre sur les marchés américains
15-03-06	USA-Les valeurs à suivre à Wall Street

1 day	+200.00%
1 week	+200.00%
1 month	+200.00%
3 months	-40.00%
6 months	+50.00%
Current year	+200.00%

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.12
5 years	0		49.8
10 years	0		401

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/17/23	TAKEDA PHARMACEUTICAL CO., LTD.	Others	Company	1,000,000	100.0000%
1/27/23	Delphi Management Partners VIII LLC	Sell	Company	121,333	2.4939%
1/23/23	Susan Molineaux	Tax	Chief Executive Officer	526	0.0108%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CALITHERA BIOSCIENCES, INC.	+200.00%	+200.00%	-70.00%	-99.40%	487
ELI LILLY AND COMPANY	+3.60%	-0.50%	+74.80%	+127.97%	1,055B
JOHNSON & JOHNSON	+3.33%	+3.55%	+53.48%	+55.80%	632B
ABBVIE INC.	+3.43%	+4.42%	+25.27%	+72.59%	442B
ROCHE HOLDING AG	+1.35%	-3.27%	+40.98%	+39.91%	351B
NOVARTIS AG	+1.75%	-0.98%	+26.20%	+39.73%	290B
ASTRAZENECA PLC	+2.13%	-1.53%	+1.85%	+9.40%	243B
AMGEN INC.	+1.41%	+1.94%	+43.45%	+61.18%	227B
NOVO NORDISK A/S	+1.35%	-3.20%	-9.07%	-53.51%	200B
GILEAD SCIENCES, INC.	+3.25%	+7.80%	+21.18%	+87.50%	172B
Average	+22.16%	-1.30%	+20.81%	+34.12%	361.25B
Weighted average by Cap.	+2.79%	-1.87%	+43.73%	+68.76%

	2021	2022
Net sales	9.75M 8.42M 7.92M 7.2M 13.54M 934M 13.74M 92.94M 36.42M 467M 36.61M 35.81M 1.56B	-
Net income	-115M -99.4M -93.52M -85M -160M -11.03B -162M -1.1B -430M -5.52B -432M -423M -18.37B	-39.65M -34.25M -32.22M -29.28M -55.08M -3.8B -55.89M -378M -148M -1.9B -149M -146M -6.33B
Net Debt	-56.5M -48.8M -45.91M -41.73M -78.48M -5.41B -79.63M -539M -211M -2.71B -212M -208M -9.02B	-23.78M -20.54M -19.33M -17.57M -33.04M -2.28B -33.52M -227M -88.85M -1.14B -89.3M -87.36M -3.8B